The present disclosure is directed toward a composite balloon comprising a layer of material having a porous microstructure (e.g., ePTFE or expanded polyethylene) and a thermoplastic polymeric layer useful for medical applications. The layers of the composite balloons become adhered through a stretch blow-molding process. Methods of making and using such composite balloons are also described amongst others.

The present disclosure is directed toward a composite balloon comprising a layer of material having a porous microstructure (e.g., ePTFE or expanded polyethylene) and a thermoplastic polymeric layer useful for medical applications. The layers of the composite balloons become adhered through a stretch blow-molding process. Methods of making and using such composite balloons are also described amongst others.

Durable, anti-fouling, crosslinked zwitterionic coatings that are grafted to the surface of a substrate through covalent bonding are disclosed. When exposed to a light source, zwitterionic monomers react with a crosslinker and with activated radicals at the surface of the substrate, simultaneously forming the crosslinked zwitterionic coating and anchoring it to the surface of the substrate. Photomasking techniques can be used to micropattern the zwitterionic coatings. The zwitterionic coatings can be applied to a variety of substrates, including medical devices and systems.

Systems and methods for localized drug delivery via undulating drug coated balloons (DCB), in particular using functionalized nanoparticles as a drug delivery medium in combination with an undulating balloon, are disclosed. In various disclosed embodiments, a nanoparticle matrix is adhered to in an external substrate-surface, such as the balloon surface, and is activated for release once at the treatment site. Activation for release may be enhanced through the use of an undulating balloon system including methodologies for precise control of timing, waveform and extent of undulations.

An example medical device includes a vascular device, such as a catheter, and an anti-thrombogenic coating on a surface of the vascular device, such as a surface likely to contact blood. The anti-thrombogenic coating includes one or more peptides configured to interact with fibrinogen in the blood, such as a first type of peptides configured to bind to fibrinogen a second type of peptides configured to inhibit conversion of fibrinogen to fibrin. The anti-thrombogenic coating also includes a polymer, such as a hydrocolloid polymer, a tunable polyethylene glycol (PEG), or other controlled release polymer configured to control release of the one or more peptides and maintain a concentration of the peptides at the surface of the anti-thrombogenic coating above a minimum inhibitory concentration, thereby inhibiting thrombin formation on the intravascular medical device.

An example medical device includes a vascular device, such as a catheter, and an anti-thrombogenic coating on a surface of the vascular device, such as a surface likely to contact blood. The anti-thrombogenic coating includes one or more peptides configured to interact with fibrinogen in the blood, such as a first type of peptides configured to bind to fibrinogen a second type of peptides configured to inhibit conversion of fibrinogen to fibrin. The anti-thrombogenic coating also includes a polymer, such as a hydrocolloid polymer, a tunable polyethylene glycol (PEG), or other controlled release polymer configured to control release of the one or more peptides and maintain a concentration of the peptides at the surface of the anti-thrombogenic coating above a minimum inhibitory concentration, thereby inhibiting thrombin formation on the intravascular medical device.

The present invention is a self-cleaning catheter designed to impede the development of biofilm within the catheter and provide a mechanism for removing biofilm within the catheter during use by a patient. The self-cleaning catheter includes an outer shell enclosing a urine lumen. The urine lumen has the ability to be opened and closed with a urine lumen closure device and is formed with a plurality of micro ports and a plurality of macro wash ports. At least one antimicrobial lumen is affixed to the exterior of and in fluid communication with the urine lumen at the plurality of micro ports. Similarly, at least one wash lumen is affixed to the exterior of and in fluid communication with the urine lumen at the plurality of macro wash ports. Antimicrobial solutions and wash solutions are introduced into the urine lumen by the antimicrobial lumen and wash lumen respectively, even during use.

A drug-releasing polymer composition is disclosed. It may include a major component, which may be ethylene vinyl acetate, and may further include at least one or two release-modifying materials, and may further include at least one or two drugs. The release-modifying materials may be polyethylene glycol and polycaprolactone. The drugs may be minocycline and rifampin. There may be an interaction such that in the presence of two different release-modifying materials, drug release may be greater than with either release-modifying material alone. There may be an interaction such that in the presence of two drugs, drug release may be greater than with either drug alone, and antibacterial performance may be enhanced. Release durations as long as two months are possible. In addition, the composition can be provided on a medical device that is configured for implanting in body tissue for an extended time period.

A drug-releasing polymer composition is disclosed. It may include a major component, which may be ethylene vinyl acetate, and may further include at least one or two release-modifying materials, and may further include at least one or two drugs. The release-modifying materials may be polyethylene glycol and polycaprolactone. The drugs may be minocycline and rifampin. There may be an interaction such that in the presence of two different release-modifying materials, drug release may be greater than with either release-modifying material alone. There may be an interaction such that in the presence of two drugs, drug release may be greater than with either drug alone, and antibacterial performance may be enhanced. Release durations as long as two months are possible. In addition, the composition can be provided on a medical device that is configured for implanting in body tissue for an extended time period.

Various embodiments disclosed relate to drug-coated balloon catheters for treating strictures in body lumens and methods of using the same. A drug-coated balloon catheter for delivering a therapeutic agent to a target site of a body lumen stricture includes an elongated balloon having a main diameter. The balloon catheter includes a coating layer overlying an exterior surface of the balloon. The coating layer includes one or more water-soluble additives and an initial drug load of a therapeutic agent.